Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NACompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Deep Vein Thrombosis of Lower LimbPulmonary Embolism (PE)Bleeding
Interventions
DEVICE

ActiveCare CECT device

Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.

DRUG

Enoxaparin

Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.

Trial Locations (9)

10021

Hospital for Special Surgery, New York

21215

Center for Joint Preservation and Replacement, Sinai Hospital of Baltimore, Baltimore

44195

Cleveland Clinic, Cleveland

46158

The center for hip and knee surgery, Mooresville

55902

Mayo Clinic, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

92037

Scripps Clinic, La Jolla

92324

Empire Orthopedic Center, Loma Linda

97701

The Center Orthopedic & Neurosurgical Care &Research, Bend

Sponsors
All Listed Sponsors
lead

Medical Compression Systems

INDUSTRY